Watch IMVT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 41, shorts 41
Insiders, 90 days
−$200K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.1BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$538.2MNET CASH —52W 14.78 – 44.96NEXT EARNINGS Nov 9 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 30 | — | — | — | — | −$153.2M | — | -0.75 | −$124.4M | — | — | Aug 6 |
| Q4 2026 · Mar 31derived | — | — | — | — | −$147.9M | — | -0.73 | −$95.1M | $8K | −$95.1M | May 20 |
| Q3 2026 · Dec 31 | — | — | — | — | −$110.6M | — | -0.61 | −$92.3M | $0 | −$92.3M | Feb 6 |
| Q2 2026 · Sep 30 | — | — | — | — | −$126.5M | — | -0.73 | −$102.5M | $0 | −$102.5M | Feb 6 |
| Q1 2026 · Jun 30 | — | — | — | — | −$120.6M | — | -0.71 | −$117.4M | $0 | −$117.4M | Aug 6 |
| Q4 2025 · Mar 31derived | — | — | — | — | −$106.4M | — | -0.63 | −$110.6M | $201K | −$110.8M | May 20 |
| Q3 2025 · Dec 31 | — | — | — | — | −$111.1M | — | -0.76 | −$100.4M | $180K | −$100.6M | Feb 6 |
| Q2 2025 · Sep 30 | — | — | — | — | −$109.1M | — | -0.74 | −$88.6M | $196K | −$88.8M | Feb 6 |
| Q1 2025 · Jun 30 | — | — | — | — | −$87.2M | — | -0.60 | −$76.2M | $182K | −$76.4M | Feb 6 |
| Q4 2024 · Mar 31derived | — | — | — | — | −$75.3M | — | -0.52 | −$59.7M | $150K | −$59.8M | May 20 |
| Q3 2024 · Dec 31 | — | — | — | — | −$51.4M | — | -0.36 | −$47.1M | $131K | −$47.2M | Feb 6 |
| Q2 2024 · Sep 30 | — | — | — | — | −$58.7M | — | -0.45 | −$60.1M | $34K | −$60.1M | Feb 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 31 | — | — | — | −$505.6M | — | -2.77 | −$407.3M | $8K | −$407.3M | — | — |
| FY2025 · to Mar 31 | — | — | — | −$413.8M | — | -2.73 | −$375.9M | $759K | −$376.6M | — | — |
| FY2024 · to Mar 31 | — | — | — | −$259.3M | — | -1.88 | −$214.2M | $360K | −$214.6M | — | — |
| FY2023 · to Mar 31 | — | — | — | −$211M | — | -1.71 | −$188.2M | $197K | −$188.4M | — | — |
| FY2022 · to Mar 31 | — | — | — | −$156.7M | — | -1.43 | −$106.1M | $254K | −$106.4M | — | — |
| FY2021 · to Mar 31 | — | — | — | −$107.4M | — | -1.22 | −$83.3M | $210K | −$83.5M | — | — |
Every number comes from Immunovant, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.